OBJECTIVE: We report our experience in providing palliative radiotherapy (RT) to patients with head and neck cancers (HNCs). Our hypofractionated regimen, "0-7-21", treats patients with 24 Gy in three fractions. METHODS: Patients, disease and response data were retrieved for candidates of 0-7-21 from 2005 to 2012. Primary end points included symptom and tumour size responses to RT based on response evaluation criteria in solid tumours (RECIST) guidelines. Secondary end points included progression-free survival (PFS) within the irradiated field, overall survival (OS) and symptomatic PFS (SPFS), calculated using Kaplan-Meier method and adverse events. Cox proportional hazards regression and logistic regression were used to investigate for prognostic factors. RESULTS: A total of 110 patients were included. Among the patients, 40% and 31% had complete response for symptoms and tumour size, respectively; 42% and 50% had partial response for symptoms and tumour size, respectively; and 15% had stability of symptoms and tumour size. Median 6-month OS was 51%, and PFS within the irradiated field was 39%. Planning target volume was predictive of OS (p < 0.001), PFS (p < 0.001) and SPFS (p < 0.005), while higher TNM stage was associated with poorer tumour response (p = 0.02). CONCLUSION: 0-7-21 is an effective and well-tolerated palliative RT regimen for patients with HNC. There was excellent symptom and local control with acceptable toxicity profile in these patients. ADVANCES IN KNOWLEDGE: This is the first study to describe the outcomes of 0-7-21 in treating advanced HNCs. The positive results suggest that 0-7-21 provides excellent palliation with minimal toxicity, with significantly less on-treatment time than current published palliative RT regimen.
OBJECTIVE: We report our experience in providing palliative radiotherapy (RT) to patients with head and neck cancers (HNCs). Our hypofractionated regimen, "0-7-21", treats patients with 24 Gy in three fractions. METHODS:Patients, disease and response data were retrieved for candidates of 0-7-21 from 2005 to 2012. Primary end points included symptom and tumour size responses to RT based on response evaluation criteria in solid tumours (RECIST) guidelines. Secondary end points included progression-free survival (PFS) within the irradiated field, overall survival (OS) and symptomatic PFS (SPFS), calculated using Kaplan-Meier method and adverse events. Cox proportional hazards regression and logistic regression were used to investigate for prognostic factors. RESULTS: A total of 110 patients were included. Among the patients, 40% and 31% had complete response for symptoms and tumour size, respectively; 42% and 50% had partial response for symptoms and tumour size, respectively; and 15% had stability of symptoms and tumour size. Median 6-month OS was 51%, and PFS within the irradiated field was 39%. Planning target volume was predictive of OS (p < 0.001), PFS (p < 0.001) and SPFS (p < 0.005), while higher TNM stage was associated with poorer tumour response (p = 0.02). CONCLUSION: 0-7-21 is an effective and well-tolerated palliative RT regimen for patients with HNC. There was excellent symptom and local control with acceptable toxicity profile in these patients. ADVANCES IN KNOWLEDGE: This is the first study to describe the outcomes of 0-7-21 in treating advanced HNCs. The positive results suggest that 0-7-21 provides excellent palliation with minimal toxicity, with significantly less on-treatment time than current published palliative RT regimen.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: K N Kancherla; D C Oksuz; R J D Prestwich; C Fosker; K E Dyker; C C Coyle; M Sen Journal: Clin Oncol (R Coll Radiol) Date: 2010-10-08 Impact factor: 4.126
Authors: B Singh; M Bhaya; J Stern; J T Roland; M Zimbler; R M Rosenfeld; G Har-El; F E Lucente Journal: Laryngoscope Date: 1997-11 Impact factor: 3.325
Authors: Abrahim Al-mamgani; Lisa Tans; Peter H E Van rooij; Inge Noever; Robert J Baatenburg de jong; Peter C Levendag Journal: Acta Oncol Date: 2009 Impact factor: 4.089
Authors: George Rodrigues; Gregory M M Videtic; Ranjan Sur; Andrea Bezjak; Jeffrey Bradley; Carol A Hahn; Corey Langer; Keith L Miller; Benjamin J Moeller; Kenneth Rosenzweig; Benjamin Movsas Journal: Pract Radiat Oncol Date: 2011-04-08
Authors: Richard Simcock; Toms Vengaloor Thomas; Christopher Estes; Andrea R Filippi; Matthew A Katz; Ian J Pereira; Hina Saeed Journal: Clin Transl Radiat Oncol Date: 2020-03-24
Authors: Jennifer Ma; Benjamin H Lok; Jingfeng Zong; Stanley I Gutiontov; Xin Cai; Andrew C Bell; Marina Shcherba; Han Xiao; Eric J Sherman; Chiaojung Jillian Tsai; Nadeem Riaz; Sean M McBride; Oren Cahlon; Nancy Y Lee Journal: Int J Part Ther Date: 2018
Authors: Aline Lauda Freitas Chaves; Ana Ferreira Castro; Gustavo Nader Marta; Gilberto Castro Junior; Robert L Ferris; Raúl Eduardo Giglio; Wojciech Golusinski; Philippe Gorphe; Sefik Hosal; C René Leemans; Nicolas Magné; Hisham Mehanna; Ricard Mesía; Eduardo Netto; Amanda Psyrri; Assuntina G Sacco; Jatin Shah; Christian Simon; Jan B Vermorken; Luiz Paulo Kowalski Journal: Oral Oncol Date: 2020-04-24 Impact factor: 5.337
Authors: Alexander Fabian; Justus Domschikowski; Markus Hoffmann; Oliver Weiner; Claudia Schmalz; Jürgen Dunst; David Krug Journal: Front Oncol Date: 2021-06-04 Impact factor: 6.244